|
|
Volumn 88, Issue 3, 2001, Pages 30-35
|
|
Safety and tolerability of apomorphine SL in patients with erectile dysfunction
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIDIABETIC AGENT;
ANTIHYPERTENSIVE AGENT;
ANTILIPEMIC AGENT;
ANXIOLYTIC AGENT;
APOMORPHINE;
CARDIAC AGENT;
DIURETIC AGENT;
DOPAMINE RECEPTOR STIMULATING AGENT;
HYPNOTIC SEDATIVE AGENT;
PSYCHOTROPIC AGENT;
ADULT;
AGED;
ARTICLE;
CEREBROVASCULAR ACCIDENT;
CLINICAL FEATURE;
CLINICAL TRIAL;
COMORBIDITY;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DISEASE COURSE;
DRUG BIOAVAILABILITY;
DRUG FORMULATION;
DRUG SAFETY;
DRUG TOLERABILITY;
ELECTROCARDIOGRAPHY;
ERECTILE DYSFUNCTION;
HEADACHE;
HEART INFARCTION;
HUMAN;
MAJOR CLINICAL STUDY;
MALE;
NAUSEA;
ONSET AGE;
PHARYNGITIS;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PHASE 3 CLINICAL TRIAL;
PRIORITY JOURNAL;
RHINITIS;
SOMNOLENCE;
TREATMENT OUTCOME;
VERTIGO;
YAWNING;
ADULT;
AGED;
ALCOHOL DRINKING;
ANTIEMETICS;
APOMORPHINE;
CARDIOVASCULAR AGENTS;
DOPAMINE AGONISTS;
DRUG INTERACTIONS;
ELECTROCARDIOGRAPHY;
HUMANS;
IMPOTENCE;
MALE;
MIDDLE AGED;
|
|
EID: 0034786840
PISSN: 14655101
EISSN: None
Source Type: Journal
DOI: 10.1046/j.1464-4096.2001.00127.x Document Type: Article |
|
Times cited : (28)
|
|
References (5)
|
